Hana Andělová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hana Andělová has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Calé
FZU - Institute of Physics of the Czech Academy of Sciences, Prague, 18200, Czech Republic; Faculty of Mathematics and Physics, Charles University, Prague, 12116, Czech Republic
2 shared publications - Oleg Lunov
FZU - Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
2 shared publications - Petra Elblová
FZU - Institute of Physics of the Czech Academy of Sciences, Prague, 18200, Czech Republic; Faculty of Mathematics and Physics, Charles University, Prague, 12116, Czech Republic
2 shared publications - Adriana De Bonis
Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, Madrid, 28040, Spain; Institute for Research in Neurochemistry (IUIN), Complutense University of Madrid, Madrid, 28040, Spain
1 shared publication Alejandro Hionides
Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, Madrid, 28040, Spain; Institute for Research in Neurochemistry (IUIN), Complutense University of Madrid, Madrid, 28040, Spain
1 shared publication- Francisco Javier Cubero
Immunology, Ophthalmology and ENT, Complutense University of Madrid Faculty of Medicine, Madrid, Spain
1 shared publication
Latest Publications
- 12 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124302
KEAP1-mediated mitochondrial remodeling on stiffness-graded collagen substrates drives hepatocellular carcinoma adaptation
- 12 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124302
KEAP1-mediated mitochondrial remodeling on stiffness-graded collagen substrates drives hepatocellular carcinoma adaptation
- Open Access
- 11 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6687
Analyzing Molecular Determinants of Nanodrugs’ Cytotoxic Effects
Nanodrugs hold great promise for targeted therapies, but their potential for cytotoxicity remains a major area of concern, threatening both patient safety and clinical translation. In this systematic review, we conducted a systematic investigation of nanotoxicity studies—identified through an AI-assisted screening procedure using Scopus, PubMed, and Elicit AI—to establish the molecular determinants of nanodrug-induced cytotoxicity. Our findings reveal three dominant and linked mechanisms that consistently act in a range of nanomaterials: oxidative stress, inflammatory signaling, and lysosomal disruption. Key nanomaterial properties like chemical structure, size, shape, surface charge, tendency to aggregate, and biocorona formation control these pathways, modulating cellular uptake, reactive oxygen species generation, cytokine release, and subcellular injury. Notably, the most frequent mechanism was oxidative stress, which often initiated downstream inflammatory and apoptotic signaling. By linking these toxicity pathways with particular nanoparticle characteristics, our review presents necessary guidelines for safer, more biocompatible nanodrug formulation design. This extensive framework acknowledges the imperative necessity for mechanistic toxicity assessment in nanopharmaceutical design and underscores the strength of AI tools in driving systematic toxicology studies.
- 11 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6687
Open AccessAnalyzing Molecular Determinants of Nanodrugs’ Cytotoxic Effects
Nanodrugs hold great promise for targeted therapies, but their potential for cytotoxicity remains a major area of concern, threatening both patient safety and clinical translation. In this systematic review, we conducted a systematic investigation of nanotoxicity studies—identified through an AI-assisted screening procedure using Scopus, PubMed, and Elicit AI—to establish the molecular determinants of nanodrug-induced cytotoxicity. Our findings reveal three dominant and linked mechanisms that consistently act in a range of nanomaterials: oxidative stress, inflammatory signaling, and lysosomal disruption. Key nanomaterial properties like chemical structure, size, shape, surface charge, tendency to aggregate, and biocorona formation control these pathways, modulating cellular uptake, reactive oxygen species generation, cytokine release, and subcellular injury. Notably, the most frequent mechanism was oxidative stress, which often initiated downstream inflammatory and apoptotic signaling. By linking these toxicity pathways with particular nanoparticle characteristics, our review presents necessary guidelines for safer, more biocompatible nanodrug formulation design. This extensive framework acknowledges the imperative necessity for mechanistic toxicity assessment in nanopharmaceutical design and underscores the strength of AI tools in driving systematic toxicology studies.